

**Osiris Therapeutics (OSIR):** Osiris is focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular arenas. Osiris currently markets and sells Osteocel for regenerating bone in orthopedic indications. Prochymal is being evaluated in Phase III clinical trials for three indications including, acute and steroid refractory Graft versus Host Disease and Crohn's disease. Prochymal is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. Osiris has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Prochymal is also being developed for the repair of heart tissue following a heart attack, and for the protection of pancreatic islet cells in patients with type I diabetes.

The Company's pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen for arthritis in the knee. Osiris is a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products.